Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521690-14-00

Enrollment

Registered

2026-05-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Brief summary

Brain connectivity assessments using MRI: A resting-state functional sequence. A T1-weighted anatomical sequence. Using a brain rsNFC study model, beta measurement values will be obtained from the images. Statistically significant changes in these beta measures will be considered relevant to the study results.

Interventions

DRUGPimavanserina 34 mg placebo cápsulas

DRUGPimavanserin tartrate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Brain connectivity assessments using MRI: A resting-state functional sequence. A T1-weighted anatomical sequence. Using a brain rsNFC study model, beta measurement values will be obtained from the images. Statistically significant changes in these beta measures will be considered relevant to the study results.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 5, 2026